This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Samalizumab

Alexion Pharmaceuticals, Inc.

Drug Names(s): anti-CD200 Mab, ALXN6000

Description: ALXN6000 is a novel anti-CD200 monoclonal antibody that blocks the binding of CD200 to its receptor.

In two separate animal models of human chronic lymphocytic leukemia (CLL), administration of ALXN6000 stimulated engrafted human immune cells to attack the CD200 expressing human tumor resulting in nearly complete inhibition of tumor growth over the course of the studies.

Deal Structure: ALXN6000 is being developed in collaboration with Dyax under its Licensing and Funded Research Program.

Partners: Shire Pharmaceuticals Group PLC


Samalizumab News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug